

Robotimize Explores ACE™ Exoskeleton Solutions Across Northern Malaysia

Robotimize introduced its ACE™ exoskeleton portfolio across care settings in Northern Malaysia, from private centres to rehabilitation institutions.

MALAYSIA, September 14, 2026

/EINPresswire.com/ -- [Robotimize](#)

Group introduced UGO, KidGo and GoGo, three exoskeletons from RoboCT within its ACE™ strategic partnerships portfolio, to healthcare providers and care communities across Northern Malaysia. The exoskeleton solutions were explored across a range of care settings, from private centres

and rehabilitation institutions to care centres, giving clinicians, caregivers and residents a chance to see the same technology considered against different sets of everyday needs, from structured clinical recovery to the ongoing demands of daily life in later years. The introduction reflects a

“

Northern Malaysia has its own healthcare landscape, and we want our technology to be genuinely useful within it, not simply present in it.”

*Kerry Guo, Founder and CEO,
Robotimize Group*

broader effort by Robotimize to reach communities across Northern Malaysia, a region historically served less by the company than the Klang Valley, and to do so with more than a single flagship device.

“Northern Malaysia has its own healthcare landscape, and we want our technology to be genuinely useful within it, not simply present in it,” said Kerry Guo, Founder and CEO of Robotimize Group.

The ACE™ strategic partnerships portfolio sits alongside

VivantePlexus™, the integrated rehabilitation technology ecosystem at Robotimize, and is designed to bring validated technologies from partnering innovators to healthcare providers and care communities across the region. UGO, KidGo and GoGo are three exoskeletons developed by RoboCT within that portfolio. Introducing all three across Northern Malaysia gave the team a chance to walk healthcare providers and care communities through the breadth of the range.



A Robotimize team member conducts the UGO demonstration to clinical staff at a hospital in northern Malaysia.

Across these settings, the exploration gave clinicians and caregivers a chance to see how exoskeleton technology from the ACE™ portfolio might sit alongside existing rehabilitation programmes, from structured, clinician-led therapy within a rehabilitation institution to the everyday mobility needs of residents in a private care centre. Rather than treating any single setting as the natural home for this kind of technology, the exploration reflected how differently the same exoskeleton range can be applied depending on who is using it and why, and how much support they need to move safely and independently. A child working through gait training, an adult recovering from a neurological condition, and an older resident focused on daily independence each represent a different point on the same continuum of care, and the ACE™ portfolio is built to serve more than one of them at once.

"Every setting we visited had different needs, and having a range of exoskeletons meant we could speak to each one directly, not with a single answer," said Even Koh, Group General Manager of Robotimize Group.

For Robotimize, introducing UGO, KidGo and GoGo across a range of care settings in Northern Malaysia was a deliberate way of showing the breadth of the ACE™ portfolio, rather than treating any one device or setting as the whole story. The portfolio model depends on matching the right external innovation to the right patient, whether that is a child working through paediatric gait training, an adult recovering from a neurological condition, or an older resident



Robotimize showcases the features of the GoGo exoskeleton at an elderly care centre in Penang.




ROBOTIMIZE | RoboCT

ACE™ Gait Rehabilitation Solutions

[Contact Us To Learn More](#)

Three images showing different users of the ACE™ gait rehabilitation range: a child, an adult, and an elderly person.

The ACE™ gait rehabilitation range from Robotimize and RoboCT.



ROBOTIMIZE | RoboCT

UGO Series

Lower Limb Exoskeleton


[Contact Us To Learn More](#)

Image of a person using the UGO Series lower limb exoskeleton.

The UGO Series, a lower limb exoskeleton within the ACE™ portfolio.

treating any one device or setting as the whole story. The portfolio model depends on matching the right external innovation to the right patient, whether that is a child working through paediatric gait training, an adult recovering from a neurological condition, or an older resident

aiming to stay mobile and confident in daily life. As with any technology introduced into a clinical or care setting, its value ultimately depends on the training, support and everyday familiarity built around it, not on the device alone, which is the kind of commitment the ACE™ portfolio is designed to provide alongside the technology itself. Introducing a range of exoskeletons together, rather than a single device in isolation, also gives healthcare providers and care communities a fuller picture of what a genuine partnership with Robotimize can look like over time.



The KidGo Series, a paediatric lower limb exoskeleton within the ACE™ portfolio.

The Northern Malaysia introduction also marks a continued push by to continue introducing technologies from its ACE™ strategic partnerships portfolio to healthcare providers and care communities across the region, working with institutions that are exploring how external innovation, across the full range from paediatric to elderly care, can be built into their own approach to rehabilitation.

About Robotimize Group

Robotimize Group is a health technology company headquartered in Singapore, specialising in intelligent rehabilitation robotics and digital neurotechnologies. Through VivantePlexus™, its integrated rehabilitation technology ecosystem, and ACE™, its strategic partnerships portfolio, Robotimize develops and distributes technologies designed to support clinician-led rehabilitation, functional training, and technology-enabled care pathways across institutional and community settings. Product availability, indications, and use are subject to applicable regulatory approvals and local clinical requirements.

For more information, visit: <http://www.robotimize.tech>

Jerry HONG
Robotimize Group
+60 11-1224 1674
[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/940829435>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something

we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2026 Newsmatics Inc. All Right Reserved.